Companies · Pharma

Intera Oncology Inc.

WELLESLEY HILLS · Pharma · refined from filed group “Other Health Care

Diligence memoA one-page analyst read on Intera Oncology Inc. — recommendation, valuation, rhythm, risks.
$3.7M
Total raised · real
3
Rounds
0.5×
Latest step-up
Top 49%
Sector rank · raised
Seed
Latest stage · inferred · Fri Jul 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Intera Oncology Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.16× the median modeled value of Seed Pharma companies in 2019–2021 (20 peers) — value vs value, same stage and era.
Dormant
  • Last raise 4.9 yr ago; this sector typically re-raises about every 16 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharma

Intera Oncology Inc. is one of 310 Pharma companies tracked from WELLESLEY HILLS. By capital raised it ranks mid-pack (ahead of 52% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

pharma

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
8
Investors (latest)
2019
Year incorporated
2021-07-30
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MSeed · 2019-03-13 Raised $2.4M (real) Modeled valuation $91M (est)$2.4M$91MSeed2019Seed · 2020-07-22 Raised $884K (real) Modeled valuation $33M (est)$884K$33MSeed2020Seed · 2021-07-30 Raised $414K (real) Modeled valuation $9.0M (est)$414K$9.0MSeed2021+$884K+$414KCumulative $3.7M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.4M · 2019
Seed extension$884K · 2020
Seed extension$414K · 2021

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$9.0M
Base estimate est.
$313K
Conservative case
$52.6M
Upside case
$2.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Seed · modeled $91.4M · 2019-03-132019Seed · modeled $32.6M · 2020-07-22Seed · modeled $9.0M · 2021-07-302021
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
34%
Survival probability
15% low · 52% high
1.68×/yr
Annual markup
2.20×/yr upside case
4.9 yr
Elapsed time used
4.9 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
14 mo
Avg between rounds
$1.6M/yr
Capital velocity
7.3 yr
On record since
2019
First round
3
Rounds on file
How it compares to the market

Benchmarked against 310 companies in Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.6× of median
This company$3.7M
Sector median$6.4M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.2× of median
This company$414K
Sector median$1.9M
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$9.0M
Sector median$62.5M

Raised more than 52% of sector peers (real $). Modeled value above 33% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #20 of 20.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Zoo Pharma Dynamics Inc. · Seed Raised $3.7M · modeled $139.3M (est)Pharma-Labs Finance LLC · Seed Raised $3.0M · modeled $114.6M (est)FSD Pharma Inc. · Seed Raised $2.6M · modeled $99.9M (est)Deepbiome Therapeutics, Inc. · Seed Raised $2.5M · modeled $95.3M (est)Pykus Therapeutics, Inc. · Seed Raised $2.5M · modeled $72.9M (est)Nexosome Oncology Holdings, Inc. · Seed Raised $3.7M · modeled $68.9M (est)BreStem Therapeutics, Inc. · Seed Raised $3.0M · modeled $68.8M (est)Ten63 Therapeutics, Inc. · Seed Raised $2.1M · modeled $62.5M (est)Plato BioPharma, Inc. · Seed Raised $3.6M · modeled $59.2M (est)Silver Therapeutics, Inc. · Seed Raised $1.5M · modeled $57.1M (est)Javelin Oncology, Inc. · Seed Raised $1.5M · modeled $57.1M (est)Small Pharma Ltd. · Seed Raised $1.9M · modeled $52.7M (est)Intera Oncology Inc. (this company) Raised $3.7M · modeled $9.0M (est)Intera Oncology Inc.
CompanyStageRaised · realValue · estvs peer med.
Zoo Pharma Dynamics Inc.Seed$3.7M$139.3M2.44×
Pharma-Labs Finance LLCSeed$3.0M$114.6M2.01×
FSD Pharma Inc.Seed$2.6M$99.9M1.75×
Deepbiome Therapeutics, Inc.Seed$2.5M$95.3M1.67×
Pykus Therapeutics, Inc.Seed$2.5M$72.9M1.28×
Nexosome Oncology Holdings, Inc.Seed$3.7M$68.9M1.21×
BreStem Therapeutics, Inc.Seed$3.0M$68.8M1.21×
Ten63 Therapeutics, Inc.Seed$2.1M$62.5M1.09×
Plato BioPharma, Inc.Seed$3.6M$59.2M1.04×
Silver Therapeutics, Inc.Seed$1.5M$57.1M1.00×
Javelin Oncology, Inc.Seed$1.5M$57.1M1.00×
Small Pharma Ltd.Seed$1.9M$52.7M0.92×
Intera Oncology Inc. this companySeed$3.7M$9.0M0.16×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.4M2019-03-13$12.0M$91.4M90%
Seed$884K2020-07-22$4.4M$32.6M90%
Seed$414K2021-07-30$2.1M$9.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.4M2019-03-13
    • First recorded raise — entered as Seed.
    • 13 investors on this round.
  2. Seed$884K2020-07-22
    • Raised 16 mo later, in step with the ~16 mo sector norm.
    • Round 2.7× smaller than the prior — bridge or down round.
    • 7 investors on this round.
  3. Seed$414K2021-07-30
    • Raised 12 mo later, in step with the ~16 mo sector norm.
    • Round 2.1× smaller than the prior — bridge or down round.
    • 8 investors on this round.
Intelligence
2022 ~Q4
Modeled next raise · ~14mo cadence
$414K
Modeled next size est.range $414K$662K
0.5×
Last step-up
$1.6M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Jonathan Reis4 other2019-03
Joseph Baron4 other2019-03
David Dove1 other2019-03
Josh Goldberg2020-07
Michael Gaisford2019-03
Registry & provenance

Intera Oncology Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1780954
SEC CIK
2019
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Atacama Therapeutics, Inc.PharmaPre-Seed$830K$4.2Mnetwork3 shared operators · same sector
Censa Pharmaceuticals Inc.PharmaceuticalsSeed$3.0M$57.1Mnetwork2 shared operators · same stage
Janus Biotherapeutics, Inc.BiotechnologySeed$2.3M$29.0Mnetwork2 shared operators · same stage
65Bio Inc.BiotechnologySeed$1.8M$77.0Mnetwork2 shared operators · same stage
Zoo Pharma Dynamics Inc.PharmaSeed$3.7M$139.3Msame sector · same stage
Nexosome Oncology Holdings, Inc.PharmaSeed$3.7M$68.9Msame sector · same stage
Plato BioPharma, Inc.PharmaSeed$3.6M$59.2Msame sector · same stage
Diligent Pharma, Inc.PharmaSeed$3.5M$34.6Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Oncology Health Partners, LlcPharmaSeries A$62.5M87%
Interline Therapeutics, Inc.PharmaSeries C$1.1B87%
Oncology Institute, Inc.Hospitals and PhysiciansSeries D+$144.7M87%
Elevation Oncology, Inc.PharmaSeries C$2.0B86%
Fuse Oncology, Inc.PharmaSeries A$79.4M85%
Atlas Oncology Holdings Inc.PharmaSeries B$85.0M85%
Civatech Oncology, Inc.PharmaSeries A$133.3M84%
Pharmaca Integrative Pharmacy IncBiotech / PharmaSeries A$234.5M84%
Frequently asked
How much funding has Intera Oncology Inc. raised?
Intera Oncology Inc. has raised approximately $3.7M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Intera Oncology Inc.'s estimated valuation?
Provath's modeled valuation for Intera Oncology Inc. is approximately $9.0M (modeled range $313K–$52.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Intera Oncology Inc. at?
Intera Oncology Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Fri Jul 30.
What does Intera Oncology Inc. do and where is it based?
Intera Oncology Inc. operates in the Pharma sector, based in WELLESLEY HILLS.
Explore related

See where Intera Oncology Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Intera Oncology Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.